Table 2

Handgrip strength of the studied population during the different days of RIF

TrialHand grip strength (N)
VRVLHRHL
Pre-experimental trial (7 days before RIF)
 CG301.55±37.36309.40±47.66304.30±36.58304±42.07
 EG294.49±55.0230.68±64.14291.06±53.74300.87±48.84
1st experimental trial (1st day)
 CG309.69±38.34314.11±46.48306.26±43.74312.83±34..62
 EG310.09±51.39315.19±49.72309.30±51.29313.81±41.38
2nd experimental trial (8th day)
 CG308.22±43.93315.09±42.17310.18±42.86312.63±38.25
 EG296.85±51.78309±55.02303.22±45.01308.03±52.47
3rd experimental trial (16th day)
 CG311.36±43.64319.70±45.70309.40±44.62313.62±36.68
 EG299.79±57.27307.14±56.88299.79±55.60299.99±51.78
4th experimental trial (22nd day)
 CG302.54±43.25311.36±50.21298.42±46.09307.73±41.48
 EG297.93±52.37310.09±59.04303.22±58.45301.36±50.41
5th experimental trial (30th day)
 CG302.54±41.48311.46±49.62295.67±41.19306.75±45.40
 EG296.55±51.58305.38±54.82304.50±55.80299.79±55.88
Postexperimental trial (15 days after RIF)
 CG301.06±40.70312.64±41.38290.57±45.52304.99±40.60
 EG295.77±50.11292.83±53.54284.88±50.70293.12±48.35
  • One way repeated measure ANOVA showed no significant difference.

  • ANOVA, analysis of variance; CG, control group (n=40); EG, experimental group (n=37); HL, horizontal left; HR, horizontal right; VL, vertical left; VR, vertical right; RIF, Ramadam intermittent fasting.